Website intended for a NZ health professional readership
This article presents some major themes from research into the impact of the COVID-19 pandemic on other viral respiratory illnesses
1. Huang QS, Turner N, Wood T, et al. Impact of the COVID-19 related border restrictions on influenza and other common respiratory viral infections in New Zealand. Influenza Other Respir Viruses 2024;18(2):e13247.
2. Turner N, Aminisani N, Huang S, et al. Comparison of the burden and temporal pattern of hospitalisations associated with respiratory syncytial virus (RSV) before and after COVID-19 in New Zealand. Influenza Other Respir Viruses 2024;18(7):e13346.
3. ESR. Respiratory Illness Dashboard.
4. Dowell A, Huang S, McIntosh C, et al. Towards new forms of communication and surveillance: a mixed methods study of rapid respiratory virus assessment in general practice during the SARS-CoV-2 pandemic. J Prim Health Care 2024;16 July online.
Pharmacist prescribers Linda Bryant and Leanne Te Karu discuss positive polypharmacy for heart failure. Current evidence shows the intensive implementation of four medications offers the greatest benefit to most patients with heart failure, with significant reductions in cardiovascular mortality, heart failure hospitalisations and all-cause mortality
